Healthcare Industry News: Bladder Cancer
News Release - November 24, 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder CancerFORT WASHINGTON, PA —(HSMN NewsFeed)--The National Comprehensive Cancer Network (NCCN), Bristol-Myers Squibb Company and ImClone Systems Incorporated have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in Bladder Cancer using cetuximab (ERBITUX®, Bristol-Myers Squibb Company/ImClone Systems Incorporated). The University of Michigan Comprehensive Cancer Center is the coordinating center for the study supported by a $1.5 Million grant.
Cetuximab is currently indicated either as a single agent or in combination for the treatment of patients who have metastatic colorectal cancer. It is also approved for the treatment of a certain type of locally or regionally advanced head and neck cancer.
“In this age of targeted therapies, it is important to explore possible new uses of agents supported by science,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “Through this grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated, we continue to provide NCCN Member Institutions with opportunities for funding of innovative cancer research, while supporting our overall mission to improve patient survival and quality of life.”
Cetuximab is an antibody that targets and binds to the epidermal growth factor receptor (EGFR), a protein found at abnormally high levels on the surface of many types of cancer cells. By binding to the EGFR on the cancer cells, cetuximab blocks the attachment of molecules that trigger the cell to grow and multiply.
“Targeting the EGFR is a validated approach to treat cancer and holds promise to improve the current results of Bladder Cancer treatment as EGFR biology is quite relevant in this tumor type,” says Eric K. Rowinsky, MD, Executive Vice President and Chief Medical Officer, ImClone Systems Incorporated. “We are pleased to support this important research that has the potential for far-reaching effects given that Bladder Cancer has an unusually high rate of recurrence.”
Bladder Cancer is the fifth most common type of cancer in the United States with an estimated 68,810 new cases diagnosed in 2008.
The NCCN Oncology Research Program (ORP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN Member Institutions. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers and establishes collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer.
For questions about NCCN or for interview information, please contact Megan Martin 215.690.0576.
About the National Comprehensive Cancer Network The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit www.nccn.org.
The NCCN Member Institutions are:
- City of Hope
- Dana-Farber/Brigham and Women’s Cancer Center
- Massachusetts General Hospital Cancer Center
- Duke Comprehensive Cancer Center
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Memorial Sloan-Kettering Cancer Center
- H. Lee Moffitt Cancer Center & Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital / University of Tennessee Cancer Institute
- Stanford Comprehensive Cancer Center
- University of Alabama at Birmingham Comprehensive Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Michigan Comprehensive Cancer Center
- UNMC Eppley Cancer Center at The Nebraska Medical Center
- The University of Texas M. D. Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.